---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-049561"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:19:59.287655+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vir Biotech Q3 net loss $163M ($1.17/sh); ECLIPSE enrollment ahead of schedule

## Summary
- Net loss $163.1M ($1.17/sh) vs $213.7M ($1.56) in Q3 2024; revenues $0.2M.
- Cash and investments $810.7M as of Sept 30, 2025; runway into mid-2027.
- ECLIPSE 1 enrollment completed ~2 months early; topline data for all three HDV studies expected Q1 2027.
- VIR-5500 first patient dosed in combo with ARPIs in 1L mCRPC; comprehensive data update planned Q1 2026.

## SEC filing metadata
- accession: 0001628280-25-049561
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828025049561/0001628280-25-049561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828025049561/vir-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-049561
- JSON: https://secwatch.observer/filing/0001628280-25-049561.json
- Plain text: https://secwatch.observer/filing/0001628280-25-049561.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.